VanEck Biotech ETF (BBH) Stock
Fund tracking leading biotech drug developers. Here's the price, business snapshot, and what's worth knowing about VanEck Biotech ETF in October 2026.
The VanEck Biotech ETF (BBH) offers investors exposure to the biotechnology sector, a key area within the broader health and life sciences industry. With a modest expense ratio of 0.35% and net assets of approximately USD 493 million, this fund holds a concentrated portfolio of 25 companies, aiming to track the performance of leading biotechnology firms. The fund has a low dividend yield of 0.40%, reflecting the sector’s focus on growth and innovation rather than income distribution. As biotechnology plays a crucial role in developing new treatments and technologies, BBH provides a way for investors to participate in these potential advancements. However, it is important to note that the biotech sector can be highly volatile due to regulatory hurdles, clinical trial outcomes, and market demand shifts. Investors should consider their risk tolerance and ensure this aligns with their overall investment strategy.
About This Stock
VANECK ETF TR BIOTECH ETF
BBH
Current Price
$246.58
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
BBH
Market Cap
N/A
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Dividend
VANECK ETF TR BIOTECH ETF does not pay a dividend, which may indicate a focus on growth rather than income. If you invested $1000 you would be paid $0 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Innovation in Health
Biotechnology is at the forefront of medical advancement. Investors might watch this ETF to track companies working on new treatments and diagnostics, though outcomes can be unpredictable.
High-Growth Potential
The biotech sector is known for its potential for rapid growth and innovation. BBH concentrates on this high-opportunity area, which comes with inherent volatility risks.
Concentrated Exposure
With only 25 holdings, BBH provides focused access to the biotech industry. This concentration means performance can be heavily influenced by specific companies and clinical developments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
